A Distinct Mechanism of Action and Delivery Platform

The distinct mechanism of action of vidutolimod has the potential to generate tumor-targeted T cells capable of killing a tumor both locally and systemically in combination with checkpoint inhibitors, thus potentially improving outcomes for people whose tumors are non-responsive to immunotherapies.

Illustration of the method of action





Ongoing Investigation in Patients

Vidutolimod is being investigated in patients with various types and stages of cancer, including melanoma and squamous cell carcinoma of the head and neck.